Form 4: Guardant Health Executive Kumud Kalia Reports Stock Transactions

Kumud Kalia, Chief Information Officer of Guardant Health, reports stock transactions including acquisition and disposal of common stock and vesting of restricted stock units.

Summary

• On March 1, 2025, Kumud Kalia, the Chief Information Officer of Guardant Health, Inc., reported transactions involving the company's stock.
• These transactions included the acquisition of 3,696 shares and 710 shares of common stock through the vesting of performance-based restricted stock units and restricted stock units, respectively, at a price of $0.
• Kalia also disposed of 1,590 shares to cover tax withholding obligations at a price of $42.55 per share.
• Following these transactions, Kalia directly owns 22,811 shares of Guardant Health common stock.
• Kalia also holds 11,090 performance-based restricted stock units and 1,421 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation. The vesting of performance-based restricted stock units is a slightly positive indicator.

Positives

• The vesting of restricted stock units indicates that performance metrics were achieved, which is a positive sign for the company.
• Kalia's continued holding of a significant number of shares and restricted stock units demonstrates confidence in the company's future.

Negatives

• The disposal of shares to cover tax obligations, while normal, slightly reduces Kalia's direct stake in the company.

Future Outlook

The remaining 67% of the performance-based restricted stock units will vest over the following two years, with 33% vesting on January 1, 2026, and 34% vesting on January 1, 2027.

Industry Context

Stock transactions by company executives are routinely monitored by investors as they can provide insights into management's confidence in the company's prospects. Vesting of restricted stock units is a common form of executive compensation in the biotech industry.

Comparison to Industry Standards

• Executive compensation packages including restricted stock units are standard practice among publicly traded biotech companies like Illumina, Exact Sciences, and Roche.
• The vesting schedules and performance-based criteria are typically aligned with long-term company goals and shareholder value creation, similar to practices observed in peer companies.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and do not signal any significant change in company outlook.

Key Dates